Document

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2019

(Exact name of registrant as specified in its charter)




Virginia	1-9810	54-1701843
(State or other jurisdiction of incorporation	(Commission File Number)	(IRS Employer Identification No.)




9120 Lockwood Blvd., Mechanicsville, Virginia		23116
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (804) 723-7000

(former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):



o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 7.01	Regulation FD Disclosure

Owens & Minor, Inc. (the “Company”) has prepared an investor presentation with information about the Company and intends to use the presentation as part of an investor conference on March 12, 2019. A copy of the presentation is attached hereto as Exhibit 99.1 and is also available at www.owens-minor.com under the Investor Relations Events & Presentations section.

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.



Item 9.01.	Financial Statements and Exhibits.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		OWENS & MINOR, INC.

March 12, 2019	By:	/s/ Nicholas J. Pace
		Name:	Nicholas J. Pace
		Title:	Executive Vice President, General Counsel and Corporate Secretary

Barclays Global Healthcare Conference March 12, 2019 | Miami, FL

Safe Harbor This presentation is intended to be disclosure through methods reasonably designed to provide broad, non- exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This presentation contains certain ''forward-looking'' statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this presentation regarding our expectations with respect to our 2019 financial performance, as well as other statements related to the company’s expectations regarding the performance of its business, growth, improvement of operational performance, and the performance of and synergies from the recently acquired Byram Healthcare and Halyard businesses. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC including the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the company’s actual results to differ materially from its current estimates. These filings are available at www.owens- minor.com. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward- looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Owens & Minor uses its web site, www.owens-minor.com, as a channel of distribution for material company information, including news releases, investor presentations and financial information. This information is routinely posted and accessible under the Investor Relations section. 2

A Global Healthcare Solutions Company SignificantSignificant Expansion Expansion with with the Byram &and Halyard Halyard $9B+ 17,000 90 In Revenue Teammates Countries Around Worldwide the Globe Extensive Portfolio of Solutions & Capabilities ~4,000+ 1,400 5 million+ Provider Facilities Manufacturer Procedures Served Partnerships Supported/Year Strategy In Place & New Leadership Team 3

Strategic Business Units 2018 Results What We Do Leading Brands . Distribution Solutions Revenue $9.2b . Provider Solutions . Op Income $104m Manufacturer Solutions . Payor Solutions Global Solutions Global . Leading surgical & Revenue $1.1b infection prevention . Wide-ranging private Op Income $76m label . Global Products Global Custom procedure trays & minor kits 4

Priorities for 2019 Retain and Win New Customers Execute Product Strategy Integrate Halyard & Realize Synergies Grow Solutions Put Business on Track for Sustainable Profitable Growth 5

Our Financial Path 2019 Headwinds: Distribution Margin Grow Distribution Revenue Solutions Realize Synergies Execute Byram Product Mfg. Solutions Retain & Win Strategy Customers Halyard Byram Provider Sol. Sell More:  Fusion5 Great: Own Preferred  Products Brands Customer Operations  Service  Productivity Improvement 6

Key Investment Themes 1 Market-leading med-surg product distribution and Channel access to approximately 1/3 of logistics provider with unique value proposition U.S. acute care market 2 Recent acquisitions increased business Strong track record of integrating diversification and position OMI for the future acquisitions; improves value proposition 3 Portfolio of leading owned products with large Halyard products occupy #1 or #2 additional penetration opportunities market positions 4 Byram is rapidly growing and the #2 player Strong presence and growth in home care in the direct-to-patient market 5 Long-standing relationships across the supply chain Average length of distribution relationship with top ten distribution customers by net with providers and manufacturers revenue is ~15 years 6 Continued demonstration of prudent capital Focus on deleveraging allocation and working capital improvement 7

Barclays Global Healthcare Conference March 12, 2019 | Miami, FL